KIT inhibition by Gleevec (imatinib) for severe asthma

May 26, 2017- Interviewed by Steven E. Greer, MD

Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers are studying whether it can reduce mast cell activity in the bronchiole system to reduce symptoms of asthma. We interviewed Michael Wechsler, MD of National Jewish Health about his paper in the NEJM.

This entry was posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology. Bookmark the permalink.

Leave a Reply

Your email address will not be published.